Skip to main navigation
Skip to search
Skip to main content
the UWA Profiles and Research Repository Home
Login
Home
Profiles
Organisations
Research output
Grants
Datasets
Prizes / Awards
Engagement / Activities
Press/Media
Units
Equipment
Impacts
Search by expertise, name or affiliation
NeuroEndocrine tumor therapy with lutetium-177-octreotate and everolimus (NETTLE): A Phase I study
P.G. Claringbold,
J Turner
Research output
:
Contribution to journal
›
Article
›
peer-review
84
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'NeuroEndocrine tumor therapy with lutetium-177-octreotate and everolimus (NETTLE): A Phase I study'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Cancer Therapy
100%
Creatinine Clearance
14%
Drug Dose Reduction
14%
Entero
14%
Everolimus
100%
Gallium 68
14%
Lutetium 177
100%
Neuroendocrine Tumor
100%
Neutropenia
14%
Pancreas Islet Cell Tumor
14%
Peptide Receptor
42%
Positron Emission Tomography-Computed Tomography
14%
Radionuclide Therapy
42%
Thrombocytopenia
14%
Pharmacology, Toxicology and Pharmaceutical Science
Creatinine
14%
Everolimus
100%
Gallium 68
14%
Lutetium 177
100%
Maximum Tolerated Dose
14%
Neuroendocrine Tumor
100%
Neutropenia
14%
Pancreas Islet Cell Tumor
14%
Radioisotope
42%
Receptor
42%
Thrombocytopenia
14%